{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T19:26:23Z","timestamp":1765826783199,"version":"3.44.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2006,7,1]],"date-time":"2006-07-01T00:00:00Z","timestamp":1151712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,7,1]],"date-time":"2006-07-01T00:00:00Z","timestamp":1151712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2006,7]]},"DOI":"10.1016\/j.amjmed.2006.05.015","type":"journal-article","created":{"date-parts":[[2006,9,28]],"date-time":"2006-09-28T15:28:41Z","timestamp":1159457321000},"page":"S93-S96","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"S1","title":["Is There a Cardiovascular Rationale for the Use of Combined Vasopressin V1a\/V2 Receptor Antagonists?"],"prefix":"10.1016","volume":"119","author":[{"given":"Steven R.","family":"Goldsmith","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjmed.2006.05.015_bib1","series-title":"Cardiac Remodeling and Failure","first-page":"17","article-title":"Therapeutics in congestive heart failure","author":"Goldsmith","year":"2003"},{"key":"10.1016\/j.amjmed.2006.05.015_bib2","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1056\/NEJMoa012630","article-title":"Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents","volume":"346","author":"Lowes","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2006.05.015_bib3","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S0735-1097(86)80417-X","article-title":"Hemodynamic effects of infused arginine vasopressin in congestive heart failure","volume":"8","author":"Goldsmith","year":"1986","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2006.05.015_bib4","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/S0735-1097(86)80333-3","article-title":"Contribution of vasopressin to vasoconstriction in patients with congestive heart failure","volume":"7","author":"Creager","year":"1986","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2006.05.015_bib5","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1071-9164(99)91339-8","article-title":"Vasopressin","volume":"5","author":"Goldsmith","year":"1999","journal-title":"J Card Fail"},{"key":"10.1016\/j.amjmed.2006.05.015_bib6","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0014-2999(99)00775-X","article-title":"Hypertrophic growth of cultured neonatal rat heart cells mediated by vasopressin V1A receptor","volume":"391","author":"Nakamura","year":"2000","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.amjmed.2006.05.015_bib7","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1023\/A:1006980517557","article-title":"Arginine vasopressin increases the rate of protein synthesis in isolated perfused adult rat heart via the V1 receptor","volume":"195","author":"Fukuzawa","year":"1999","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.amjmed.2006.05.015_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1677\/jme.0.0290001","article-title":"Vasopressin V2 receptor antagonists","volume":"29","author":"Verbalis","year":"2002","journal-title":"J Mol Endocrinol"},{"issue":"suppl","key":"10.1016\/j.amjmed.2006.05.015_bib9","doi-asserted-by":"crossref","first-page":"14B","DOI":"10.1016\/j.amjcard.2005.03.004","article-title":"Current treatments and novel pharmacologic treatments for hyponatremia in congestive heart failure","volume":"95","author":"Goldsmith","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjmed.2006.05.015_bib10","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1001\/jama.291.16.1963","article-title":"Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure","volume":"291","author":"Gheorghiade","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2006.05.015_bib11","first-page":"1308","article-title":"Furosemide in the long-term management of heart failure","volume":"44","author":"Weber","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2006.05.015_bib12","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1161\/01.CIR.100.12.1311","article-title":"Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction","volume":"100","author":"Cooper","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2006.05.015_bib13","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/j.jacc.2004.04.059","article-title":"Furosemide and the progression of left ventricular dysfunction in experimental heart failure","volume":"44","author":"McCurley","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2006.05.015_bib14","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/S0022-3565(24)35289-9","article-title":"Effects of the V2-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats","volume":"292","author":"Hirano","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.amjmed.2006.05.015_bib15","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1161\/01.CIR.0000165065.82609.3D","article-title":"Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure","volume":"111","author":"Klein","year":"2005","journal-title":"Circulation"},{"issue":"pt 2","key":"10.1016\/j.amjmed.2006.05.015_bib16","first-page":"H2245","article-title":"Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs","volume":"267","author":"Naitoh","year":"1994","journal-title":"Am J Physiol"},{"key":"10.1016\/j.amjmed.2006.05.015_bib17","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0008-6363(02)00244-4","article-title":"Neurohormonal antagonism in heart failure; beneficial effects of vasopressin V1a and V2 receptor blockade and ACE inhibition","volume":"54","author":"Naitoh","year":"2002","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.amjmed.2006.05.015_bib18","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1161\/hc4501.099313","article-title":"Acute hemodynamic effects of conivaptan, a dual V1A and V2 vasopressin receptor antagonist, in patients with advanced heart failure","volume":"104","author":"Udelson","year":"2001","journal-title":"Circulation"},{"issue":"suppl","key":"10.1016\/j.amjmed.2006.05.015_bib19","first-page":"S120","article-title":"Novel vasopressin V1a and V2 antagonist (conivaptan) increased serum sodium concentration in patients with hyponatremia secondary to congestive heart failure","volume":"11","author":"Verbalis","year":"2005","journal-title":"J Card Fail"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000293430600550X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000293430600550X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T08:43:07Z","timestamp":1757580187000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000293430600550X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7]]},"references-count":19,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2006,7]]}},"alternative-id":["S000293430600550X"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2006.05.015","relation":{},"ISSN":["0002-9343"],"issn-type":[{"type":"print","value":"0002-9343"}],"subject":[],"published":{"date-parts":[[2006,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is There a Cardiovascular Rationale for the Use of Combined Vasopressin V1a\/V2 Receptor Antagonists?","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2006.05.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}